Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Duble Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of Insulin Lispro (LLC "GEROPHARM", Russia) Versus Humalog® (Eli Lilly) in Healthy Subjects Using the Euglycemic Clamp Technique

Trial Profile

A Randomized Duble Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of Insulin Lispro (LLC "GEROPHARM", Russia) Versus Humalog® (Eli Lilly) in Healthy Subjects Using the Euglycemic Clamp Technique

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GEROPHARM
  • Most Recent Events

    • 01 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top